Results: A total of 35 published trials were included. Approximately two-thirds of the articles clearly indicated the level of blinding. Only 26% reported a primary outcome measure. Less than half explicitly reported the number of patients who completed the trial, and only 1 reported a method that was used to accommodate missing data. Almost one-third of articles included a responder analysis, all of which specified the definition of a responder.
Conclusions:
The goal of highlighting these deficiencies in reporting is to promote transparent reporting of details affecting the completion and interpretation of procedural cancer pain trials so that their quality can be more easily evaluated. A nalgesic treatments provide sufficient relief for many people with cancer pain but may provide inadequate relief for many others. 1 Procedural therapies (eg, epidural or spinal drug delivery, peripheral nerve or plexus block/ablation, percutaneous vertebral augmentation) may be useful in providing improved pain relief. 2, 3 When evaluating trials of procedural interventions for cancer pain, it is important to consider the methodological challenges inherent to analgesic trials (eg, dependence on subjective measures of outcome), procedural trials (eg, difficulty blinding), and trials with cancer patients (eg, comorbid conditions and potential for increased dropout and mortality) and how the combination of these challenges can affect completion and interpretation of trials of procedural treatments for cancer pain.
An important methodological issue central to all clinical trials is prespecification of the primary outcome measure to ensure an unbiased interpretation of the results. [4] [5] [6] In pain trials, specification of the primary outcome measure requires a clear definition of the type of pain and the time frame the participants should consider when rating their pain. Research has shown that patients experiencing pain often consider other factors (eg, interference in sleep and physical activity) when rating their pain intensity. 7 This can lead to increased variability in ratings, especially if patients are not consistent in the factors they consider when rating their pain over the course of the study. 8, 9 Ratings may not reflect the pain intensity of particular interest when a patient experiences pain from many sources, not all of which are targeted by the specific treatment, as may be the case for cancer patients. Therefore, when communicating with clinical trial participants, it is important for researchers to describe the type and location of pain that they would like the participants to focus on and rate. 8 Blinding patients and investigators in procedural trials can be difficult. A sham procedure that completely blinds participants and researchers who perform follow-up assessments might be ideal methodologically but may be unethical with high-risk procedures, 10 and blinding providers may be particularly difficult. Use of an active control group may be a viable alternative strategy; however, it is only possible to blind assessors and sometimes patients in such trials. In addition, it is difficult to show that a new treatment is more effective than an existing treatment, and demonstrating that 2 treatments have equivalent efficacy requires larger sample sizes than demonstrating that one treatment is superior to another.
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Recruitment and retention may be particularly difficult in trials that include cancer patients because of the presence of both physiological and psychiatric comorbidities and high mortality rates. Cancer patients are often enrolled in oncologic treatment trials, which could interfere with their eligibility for participation in trials of procedural pain treatments; moreover, patients and their families may be reluctant to participate in a cancer pain trial in which they could be randomized to a more conservative treatment arm. Furthermore, many oncologists tend to prefer treating patients with opioid analgesics and may be reluctant to refer their patients to randomized clinical trials (RCTs) for procedural pain treatments. These barriers can make it difficult to maintain sufficient statistical power to detect treatment effects in clinical trials. 12, 13 Cancer pain may increase during the study along with disease progression or ongoing cancer treatments. Potentially unstable pain levels can increase variability in pain intensity ratings and decrease assay sensitivity (ie, the ability to detect a true treatment effect). Furthermore, studies that investigate treatments for pain and other symptoms related to cancer, as opposed to treatments to cure cancer, may not be as high of a priority to clinicians and patients, leading to additional difficulties with recruitment and retention. 14 The challenges outlined highlight the importance of clearly reporting participant flow, as well as methods to accommodate missing data, when evaluating procedural treatments for cancer pain.
In addition to optimizing the validity of the trial results, maximizing the clinical interpretation is also important. A "responder" analysis that compares the percentage of participants in each treatment group that achieved a specific response (eg, ≥30% or ≥50% reduction in pain from baseline) may help clinicians evaluate the clinical meaningfulness of a treatment effect. 15, 16 Another important factor when evaluating the clinical benefit of a treatment is understanding and weighing its associated risks against the benefits; therefore, it is necessary for articles to adequately report adverse events. 17 The objective of this systematic review was to investigate the reporting of RCTs that evaluated procedural treatments for cancer pain, focusing on how the challenges described previously have been addressed. As part of the activities of ACTTION (Analgesic, Anesthetic and Addiction Trials, Translations, Innovations, and Opportunities Network) public-private partnership focused on improving clinical trial methods, we provide recommendations for the execution and reporting of the results of procedural treatment trials for cancer pain with the hope of facilitating progress in identifying efficacious treatments for refractory cancer pain.
METHODS

Article Selection
In this systematic review, we evaluated reports of RCTs for procedural interventions to treat cancer pain that were published between the start of PubMed (1966) and June 2014 (Appendix, Supplemental Digital Content 1, http://links.lww.com/AAP/ A186). Trials evaluating post-cancer surgery-related pain were excluded. Procedural interventions were defined as percutaneous, minimally invasive procedures for the purpose of pain relief (eg, epidural or spinal drug delivery, peripheral nerve or plexus block/ablation, percutaneous vertebral augmentation). Surgical procedures, such as open spinal surgery, cordotomy, tumor debulking, and palliative radiation, were excluded. Eligible trials could use any measure to record pain data, did not have to be blinded, could include either adult or pediatric patients, and required a procedural intervention in at least 1 arm of the trial. The articles were each screened for inclusion by D.R. and R.A. K. independently.
Data Extraction
A coding manual was developed to evaluate the reporting of trial design details in procedural cancer pain trials, as well as the fulfillment of the 10 CONsolidated Standards of Reporting Trials (CONSORT) harms reporting recommendations 17 (Appendix, Supplemental Digital Content 2, http://links.lww.com/AAP/A187).
The CONSORT group publishes various guidelines to promote improved reporting of clinical trials (http://www.consort-statement.org/). The manual was pretested and modified for content and clarity by J.S.G., D.R., and S.M.S. in 3 rounds, which comprised 2 rounds of 3 articles each and a third round of 2 articles. R.A.K. was then trained on the procedures and definitions included in the coding manual using the same set of articles that were used during the pretest rounds. The final list of included articles was organized into 2 randomized lists, and each article was coded by 2 independent coders (D.R. and R.A.K.). After all of the articles had been independently coded, R.A.K. reviewed the data and corrected all discrepancies due to obvious oversight. Discrepancies that were due to differences in interpretation were adjudicated by R.A.K., with input from J.S.G. and S.M.S. In the case of trials with a medication management group, we categorized this as protocol defined if the specific medications to be used were defined in the protocol or the protocol instructed investigators to follow the World Health Organization cancer pain treatment guidelines. 1 In the articles that reported trials that were designed to test the hypothesis that one active treatment was better than another (ie, superiority design) and reported a nonsignificant result, we identified whether the authors made any claims of comparable efficacy between groups (eg, both treatments "provided an equivalent extent of pain relief "; "both 1-injection and 2-injection methods were equally safe and efficacious").
Statistical Analyses
Descriptive statistics were used to analyze all trial characteristics and trial design details, including pain assessment and CON-SORT harms reporting recommendations. Statistical comparisons of reporting quality between subgroups were not performed because of the small number of trials identified. We did, however, compare the percentages of articles that clearly reported design and statistical details between early (ie, articles published between 1985 and 2004) and late (ie, articles published between 2005 and 2014) periods using descriptive statistics. A prespecified cutoff of a difference of 10 percentage points between periods was considered noteworthy and reported and discussed in the article. We chose this date because it split the sample approximately in half and yielded a later set of articles that was published in a similar time frame to those covered in previous reviews, allowing for comparison.
RESULTS
Coder Discrepancies
We coded a total 1340 survey questions for the entire sample of articles, and 333 discrepancies (25%) occurred. Of the 333 discrepancies, 213 (64%) were due to obvious oversights by one of the coders, and the remaining 120 (36%) were due to differences in interpretation.
Trial Characteristics
A total of 755 records were identified through the database search; 697 were eliminated by screening the titles or abstracts. We eliminated an additional 23 articles after screening the full text because they were not RCTs or the treatment was not specific for cancer pain, leaving 35 articles that met the eligibility criteria ( Fig. 1 ; also, Appendix, Supplemental Digital Content 3, http://links.lww.com/AAP/A188). Almost half (43%) of these articles were published between 2005 and 2014. Most (83%) had a parallel-group study design. The median number of participants randomized was 47 (interquartile range [IQR], 21-71).
The most common types of interventions studied were peripheral nerve blocks, including sympathetic/plexus blocks (46%), drugs delivered via epidural administration (23%), drugs delivered via intrathecal injection (20%), and percutaneous vertebral augmentation (9%). More than half (69%) of the articles used another active procedural treatment as the comparison group, followed by noninvasive medication management defined by the trial protocol (17%). Three articles reported using a sham procedure control (Table 1) .
Twenty-five (71%) of the reports described pain-related eligibility criteria, of which previous failure of conservative treatment (n = 15, 60%) and minimum baseline pain were most common (n = 11, 44%). Those with mental health disorders were excluded in 8 trials (32%) ( Table 1) . Twenty-two articles (63%) stated that preintervention pain medications were allowed to continue during the trial. Eleven (50%) permitted any concomitant pain medication, 14 (64%) permitted any rescue pain medication, and 8 (36%) allowed specific concomitant or rescue pain medications.
Although only 12 articles (34%) reported the eligibility criteria pertaining to types of cancer, the primary cancer types of the enrolled patients were specified in 30 (86%) of the articles. Within those 30 articles, 20 (67%) included 2 or more cancer types, and 10 (33%) included only a single cancer type. Almost three-quarters (71%) of reports did not state whether metastatic or nonmetastatic cancer types were included, and of the remaining 10 articles, 8 (80%) reported that both metastatic and nonmetastatic cancer types were included.
Approximately half of the articles (49%) did not report sponsorship for the trial; of the 18 articles that did, 9 indicated industry sponsorship. Approximately two-thirds (63%) of the articles clearly indicated the level of blinding in the trial; 26% of the trials were double blind, 9% were single blind (ie, participant blinded), 11% were assessor-only blinded, and 9% of the articles reported that the participant and all study staff except the person performing the intervention were blind ( Table 1 ). The percentage of articles that clearly indicated the level of blinding increased in the late period (55% early period vs 73% late period).
Primary Outcome Measure and Assessments
Most (83%) of the articles did not specify a primary outcome measure. Six articles defined a primary outcome measure, including the time at which the primary outcome measure would be analyzed; all of these also specified the primary method for statistical analysis. However, only 1 indicated that the primary outcome measure was prespecified or protocol defined ( Table 2 ). The primary outcome measures varied, including the following: (1) 100-mm visual analog scale for pain, (2) 0-to 10-point numeric pain rating scale (NRS), (3) Roland Morris Disability Questionnaire, (4) percent change in pain intensity, (5) achievement of pain relief (defined as <20 on a 0-to 100-point NRS), and (6) achievement of 20% or greater improvement in pain of composite drug-related toxicity score using the National Cancer Institute Common Toxicity Criteria. The majority of articles (86%) did not state that the participants were given any specific instructions on how to assess their pain. The reported instructions included asking participants to rate their (1) pain at rest and nighttime pain, (2) average daily pain, (3) "global pain" at 9:00 am and 9:00 pm, and (4) back pain specifically (2 articles). Six articles reported the type of pain that was assessed (ie, average, least, worst, current, or multiple of these). The most common maximum frequencies of pain ratings throughout the studies were daily or multiple times daily (n = 12, 34%), and weekly or every other week (n = 11, 31%). The duration of follow-up was highly variable between studies, ranging from as short as 1 day to until the participants died (Table 2) . Fifteen articles (43%) stated where the follow-up assessments were performed. The most frequently reported follow-up assessment locations were at home (n = 9, 60%) and the clinic, hospital, or study site (n = 7, 47%). Only 11 articles (31%) reported the total number of times the participant was required to return to the clinic for a visit. This percentage improved in the more recent set of articles (20% early vs 47% late). Three articles (9%) stated that there were no follow-up visits, and the 32 remaining articles did not specify whether the follow-up visits were scheduled with nontrial clinic visits.
Participant Flow, Data Analyses, Accommodation of Missing Data, and Interpretation
The number of trial completers was reported in 14 articles (40%), with a median of 88% (IQR, 69%-97%) of participants completing the studies that reported this information. The number of participants included in the analyses was stated in 20 articles (57%). Only 1 article reported a method to accommodate missing data (ie, mixed-effects analysis of variance).
Eleven articles (31%) provided a responder analysis. All 11 articles that reported a responder analysis defined the criteria used to establish who qualified as a responder. The following definitions for responders were used: (1) those who reached a prespecified low-level pain score (eg, pain decreased to <20 on a 0-to 100-point NRS) (n = 5), (2) a participant with complete pain relief (n = 3), (3) 20% or greater pain relief (n = 1), (4) 30% or greater pain relief (n = 1), and (4) any reduction in pain or morphine consumption (n = 1).
Of the 30 articles using either another active procedural treatment or a defined noninvasive medication management protocol as the control arm, 22 (73%) did not find a statistically significant difference between treatments. Eight articles (36%) went on to imply that the treatments were "equally efficacious" based on nonsignificant results of trials designed to test superiority. Furthermore, none of these articles provided a confidence interval for the treatment effect to support implications of equivalent efficacy.
CONSORT Harms Reporting Recommendations
The 10 CONSORT harms reporting recommendations were fulfilled to varying degrees, with only 1 item (ie, reporting the denominators for harms data) reported more frequently in the late time period, which occurred after the harms reporting guidelines were published. See Table 3 for the detailed results on CONSORT harms reporting recommendations.
DISCUSSION
This review identified significant deficiencies in reporting and interpretation of RCTs of procedural treatments for cancer pain, only a few of which appear to have substantially improved in the past decade compared with the previous 2 decades. When comparing the cancer pain articles published between 2005 and 2014 to available reviews of analgesic trials for any pain condition published between 2006 and 2012, the cancer pain articles reported the following detail less frequently: (1) primary analysis (20% vs 68% 5 ), (2) methods to accommodate missing data (0% vs 45% 18 ), (3) withdrawals due to harms (20% vs 58% 19 ), and (4) reporting of instructions provided to patients about the type of pain to be assessed (eg, worst vs average) (26% vs 57% 20 ). Clear and unambiguous reporting of the design and statistical details described previously and others is essential for readers to critically evaluate trial results. We summarize the concepts that are particularly challenging or pertinent when designing, reporting, and reading reports of RCTs of procedural interventions for cancer pain below and in Table 4 . It is beyond the scope of this review to cover, in detail, all important issues related to design, analysis, and reporting of RCTs. Our suggestions should be used to highlight unique considerations for procedural cancer pain trials in combination with general guidelines such as the CONSORT statement. 21 Blinding of group assignments is important to minimize bias in all clinical trial outcomes; this is especially true when the outcomes are subjective, as with participant-reported pain. 22 Furthermore, when it is not feasible to blind participants and clinicians to the treatment assignments, premature dropout may occur when participants are assigned to the obvious control group, which can lead to a form of selection bias. Although it may be challenging to blind procedural trials, it is important to make and clearly describe any and all attempts that were made to blind participants, investigators, nonstudy physicians, procedural physicians, and outcome assessors so that readers can evaluate the potential bias from lack of blinding in these trials.
When assessing pain, it is important to provide instructions pertaining to which type of pain the participants are expected to rate. 20 Provision of such instructions may decrease the variability in pain assessments by focusing participants' attention on the type, timing, and location (eg, specific body part or worst site) of the pain of interest rather than having participants assume what pain to rate. 8, 20 Decreasing the variability in outcome measures may increase the assay sensitivity of a trial, 23 as long as it does not decrease the magnitude of the signal. In addition, such instructions may increase the validity of the trial because the outcome measure will more likely reflect true ratings of the pain of interest. Focusing participants' attention on specific types of pain can be especially important for cancer patients who may have multiple sources and locations of pain. Any special instructions provided to patients for pain rating outcomes should be described in the publications of all clinical trials.
A high percentage of missing outcome data can negatively affect the validity of the trial results. 18, [24] [25] [26] [27] [28] Missing data are likely to be an issue in cancer pain trials because cancer patients have increased rates of morbidity and mortality. 12, 13 When data are missing, prespecified statistical approaches to accommodate missing data should be used. It is impossible to recommend a single method to accommodate missing data because all of the methods depend on assumptions about the missingness mechanism. Statisticians and regulatory agencies suggest specifying a primary method (eg, direct likelihood, multiple imputation, inverse probability weighting) that assumes a particular missingness mechanism (eg, missing at random) and adding sensitivity analyses that vary the assumptions regarding the missingness mechanism to see how strongly the results depend on the assumptions that are made. In addition, they discourage use of single imputation methods such as last (or baseline) observation carried forward that make unrealistic assumptions and artificially increase the precision of the estimates of interest. 18, [24] [25] [26] [27] [28] The number of participants who are randomized, complete the trial, and are included in the analyses, as well as the methods used to accommodate missing data and whether they were prespecified, should be clearly outlined in peer-reviewed publications.
A responder analysis can provide additional information for clinicians to interpret the clinical meaningfulness of a treatment effect. 15, 16 However, it is important that the definition and criteria used to designate a responder are prespecified in the design of the trial and clearly reported in articles. A complementary option for displaying the data is a cumulative proportion of responders curve, which plots the percentage of responders over a comprehensive range of response definitions (eg, ≤0% to 100% decrease in pain) 29 The cumulative proportion of responders for the treatment groups can be compared using a rank test. This analysis eliminates the requirement to prespecify a specific response definition and allows for interpretation over the entire range of response definitions.
Many of the trials we reviewed compared 2 active treatment groups, possibly because it is often difficult to create a placebo for procedural interventions, oncologists may hesitate to refer cancer patients, or the patients and their families may be reluctant to be randomized to an inactive treatment. It is important to note that conclusions of comparable efficacy based on a nonsignificant statistical test of superiority may not be valid. 11 Reporting the confidence interval for the between-group difference (ie, treatment effect) allows readers to evaluate whether the data remain 
Design considerations
• Make attempts to blind participants, investigators, and assessors to the treatment groups to the extent possible • Prespecify primary outcome measures and analyses • Prespecify a definition for a "responder" if a responder analysis will be performed • Prespecify methods to accommodate missing data that make realistic assumptions about the missingness mechanism • Provide instructions to participants on which types, characteristics, and locations of pain to assess • Use a noninferiority or equivalence trial design if the experimental treatment will be compared with another active treatment and the goal of the study is to demonstrate that the experimental treatment has comparable efficacy to that of the other treatment Reporting recommendations
• Provide details regarding blinding of participants, investigators, and assessors • Clearly describe important clinical trial design considerations • Explicitly state the number of participants who completed the trial • Explicitly state the number of participants included in the analyses • Provide reasons for participant withdrawal • Indicate the method that was used to accommodate missing data in the statistical analyses • Report harms according to the CONSORT recommendations 17 • Do not conclude comparable efficacy of 2 treatments based on a nonsignificant treatment difference in a superiority trial consistent with a clinically meaningful difference between groups despite the absence of statistical significance. However, it is important to note that even when the confidence intervals support a conclusion of no clinical difference between treatment groups, such conclusions should be evaluated using sufficiently powered and designed noninferiority studies. 11, 30, 31 In a correctly executed noninferiority study, the maximum observed difference between the new treatment and the standard treatment that would not be considered clinically meaningful is determined a priori and used to set a noninferiority margin. The lower confidence bound for the difference in, say, mean response between the new treatment and the standard treatment must fall above this noninferiority margin for the new treatment to be declared "noninferior." 11, 30, 31 The limitations of concluding comparable efficacy from superiority trials should be acknowledged in manuscripts and considered by readers when interpreting the results of clinical trials.
This review has limitations that should be acknowledged. We were able to evaluate only what was reported in published articles and not what was actually done by the investigators. Because our objective was to examine the adequacy of the reporting of clinical trials, and we made no attempt to evaluate the efficacy of the interventional procedures studied within the trials, our results should not be used as justification to deny care or payment for care to cancer patients who might benefit from procedural treatments. Furthermore, we recommend that healthcare providers and payers not draw conclusions on treatment efficacy based on our results. Clearly, a multimodal approach (inclusive of procedural interventions as indicated) is optimal for the treatment of cancer pain. We only examined RCTs of interventional techniques used to treat cancer pain, and thus, these results may not be generalizable to trials of interventional treatments for other types of pain or for noninterventional techniques evaluated for cancer pain. Finally, we have not evaluated reporting of all important study details that could affect the validity of the study results. We did not consider those that we felt were not uniquely challenging in the setting of procedural interventions for cancer pain studies (eg, process of generating randomization assignments).
Randomized clinical trials of procedural treatments for cancer pain tend to have many challenges, including identifying appropriate control groups, limitations in blinding, recruiting sufficient numbers of participants, minimizing participant dropout during a medically challenging time in participants' lives, and rates of mortality for advanced metastatic disease. Clearly reporting details regarding study design, methods for statistical analysis, and results is necessary for readers to be able to evaluate the level of evidence provided by these clinical trials. We believe that highlighting areas in need of improvement will lead to clearer reporting and therefore allow for critical interpretation of cancer pain trials and the determination of the validity of their results.
